コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ion in the skin alone is sufficient to drive inflammatory joint disease.
2 s that are implicated in the pathogenesis of inflammatory joint disease.
3 We also determined TSG-6 expression in inflammatory joint disease.
4 novel target for therapeutic intervention in inflammatory joint disease.
5 t has been implicated in the pathogenesis of inflammatory joint disease.
6 , 49 of the 63 patients (78%) had persistent inflammatory joint disease.
7 is provide a window into the pathogenesis of inflammatory joint disease.
8 -1 gene products in initiating or amplifying inflammatory joint disease.
9 Osteoarthritis (OA) is a low-grade chronic inflammatory joint disease.
10 namics involved in tumor angiogenesis and in inflammatory joint diseases.
11 d their activation-induced microparticles in inflammatory joint diseases.
12 to BM-MSC to potentially treat degenerative/inflammatory joint diseases.
13 and juvenile idiopathic arthritis among the inflammatory joint diseases.
14 lpha) therapies for non-rheumatoid arthritis inflammatory joint diseases.
15 ing expression of the cartilage phenotype in inflammatory joint diseases.
16 tilage destruction that is characteristic of inflammatory joint diseases.
17 s contribute to the onset and progression of inflammatory joint diseases.
18 , a drug initially used for the treatment of inflammatory joint disease and only later in the treatme
19 receptor blockade in a therapeutic model of inflammatory joint disease and provide support for pursu
21 ajor advance in the treatment of a number of inflammatory joint diseases and have been widely availab
22 Rheumatoid arthritis (RA) is the most common inflammatory joint disease, and early diagnosis is key f
24 n rheumatoid arthritis (RA), the most severe inflammatory joint disease, autoantibodies against citru
26 thritis (RA), the severity of autoimmune and inflammatory joint disease correlates with large numbers
27 erantigens on the development of autoimmune, inflammatory joint disease in animals that are susceptib
28 significantly ameliorated the development of inflammatory joint disease in mice challenged with colla
32 nflammation is most commonly associated with inflammatory joint diseases, it also occurs in OA and is
33 ercise/joint mobilization is therapeutic for inflammatory joint diseases like rheumatoid and osteoart
35 lling effect on the development of Ag-driven inflammatory joint disease, possibly by mediating the re
36 t acquired lubricin degradation occurring in inflammatory joint diseases predisposes the cartilage to
38 ical agents for the treatment of the chronic inflammatory joint disease rheumatoid arthritis has rein
39 exRNA and its antagonist RNase1 in a chronic inflammatory joint disease, rheumatoid arthritis (RA).
40 ngiogenic treatment may reduce the burden of inflammatory joint diseases such as rheumatoid arthritis
41 orks represent common effector mechanisms in inflammatory joint diseases such as rheumatoid arthritis
42 y apoptosis contributes to cartilage loss in inflammatory joint diseases, such as rheumatoid arthriti
43 States to treat refractory synovitis in many inflammatory joint diseases, such as rheumatoid arthriti
44 was grown) and controls (non-Lyme arthritis inflammatory joint disease, syphilis, multiple sclerosis
45 radative processes are better documented for inflammatory joint diseases than tendinopathy even thoug
46 xin are apparent in rheumatoid arthritis, an inflammatory joint disease that disables millions of peo
48 atment-resistant Lyme arthritis is a chronic inflammatory joint disease that follows infection with B
49 3 is a critical proinflammatory cytokine for inflammatory joint disease that integrates fibroblast ac
50 SM and highlight new therapeutic targets for inflammatory joint diseases that aim to repress the expr
51 To determine the effect of TSG-6 on chronic inflammatory joint disease, we induced CIA in DBA/1J mic